Market Size – USD 1.08 Billion in 2019, Market Growth – CAGR of 17.6%, Market Trends – High demand in cognitive analytical insights
The Global Minimally Invasive Biopsy Technologies Market is projected to reach USD 3.98 billion in 2027. The market is expected to be driven due to a higher proliferation of the minimally invasive surgical procedures in biopsy testing and an extensive rise in the rate of breast and lung cancers globally. Around 66% of the total initial breast biopsies performed in North America are minimally invasive breast biopsies (MIBB).
Considerable numbers of the overall open excisional biopsy have been replaced by the minimally invasive biopsy technology in patients having the imaging-detected suspicious or the indeterminate breast lesions. With minimally invasive surgeries in the biopsy, higher precisions can be accumulated, which in turn helps in reducing the psychological burden that affects the patients and also helps reduce the overall cost by a significant margin.
The extensive proliferation of the minimally invasive surgical technologies and extensive rise in the requirement of biopsy tests to diagnose cancerous cells and identifying infectious, autoimmune disorders and inflammatory cases. Early detection of the cancers and higher precision compared to incisional and excisional biopsies have been the constant driving factors for this market.
Key players in the market include Chronix Biomedical, Biocept, Inc., F. Hoffmann-La Roche Ltd, Mauna Kea Technologies, Veracyte, Inc., Thermo Fisher Scientific, NeoGenomics Laboratories, Inc., Abcodia Ltd., Adaptive Biotechnologies, and Owlstone Medical Ltd., among others.
Browse complete report description and visit our website @ https://www.emergenresearch.com/industry-report/minimally-invasive-biopsy-technologies-market
Regional Scope: North America; Europe; Asia Pacific; Central & South America; MEA
Technology Outlook (Revenue: USD Billion; 2017-2027)
- Liquid Biopsy
- Optical Biopsy
- Brush Biopsy
- Pigmented Lesion Assays
- Breath Biopsy
- Brush Biopsy
- Others
Therapeutic Application Outlook (Revenue: USD Billion; 2017-2027)
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Blood Cancer
- Non-oncology Applications
End-Use Verticals Outlook (Revenue: USD Billion; 2017-2027)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Cancer Research Institutes
- Others
North America accounted for the largest market share of approximately, 37.2% in the global Minimally Invasive Biopsy Technologies market in 2019 primarily due to growing incidences of chronic asthma and rhinosinusitis symptoms along with competent infrastructure and favorable reimbursement scenarios. Owing to such promising market drivers, the North American market is anticipated to grow significantly through the forecast period.
Thank you for reading our report. For further information or queries about the report or customization options, please get in touch with us. We will ensure your report is tailored according to your requirements.

